摘要
目的探讨直接抗病毒药物(DAAs)对肾移植术后的丙型病毒性肝炎(HCV)的临床效果。方法选取医院于2018年4月—2019年4月收治的6例肾移植术后HCV患者,均采用DAAs方案进行治疗,即4例单药索非布韦,1例雷迪帕韦+索非布韦,1例达卡他韦+索非布韦,持续治疗12周。结果治疗4周后,HCV RNA定量即转阴5例,且疗程后得到持续性病毒学应答(SVR),1例单纯给药索非布韦患者,疗程后HCV病毒载量仍较正常值偏高,而改为达卡他韦+索非布韦治疗12周,其病毒载量转阴,且获得SVR。不良反应:1例一过性皮疹,1例轻度眩晕。结论采用DAAs治疗肾移植术后HCV患者,效果好,安全性高。
Objective To investigate the clinical effects of direct antiviral drugs(DAAs) on viral hepatitis C(HCV) after renal transplantation. Methods 6 patients with HCV after renal transplantation admitted to our hospital from April 20 to April 2019 were treated with DAAs. Four patients were treated with solifenide, and one patient was treated with dexhipivir and one patient. Non-Bouwei, 1 case of d’Axavir + sofobuvir, continued treatment for 12 weeks. Results After 4 weeks of treatment, HCV RNA was negatively quantified in 5 cases, and a continuous virological response(SVR) was obtained after treatment. One patient was treated with sofosbuvir alone. The HCV viral load was still lower than the normal value after the treatment. High, and changed to dartarevir + sofobuvir for 12 weeks, its viral load turned negative, and SVR was obtained. Adverse reactions: 1 case of transient rash, 1 case of mild vertigo. Conclusion The use of DAAs in the treatment of HCV patients after renal transplantation has good efficacy and high safety.
作者
王红
韦晓瑞
WANG Hong;WEI Xiaorui(6 Treatment Areas,Jilin Hepatobiliary Hospital,Changchun Jilin 130021,China)
出处
《中国继续医学教育》
2020年第21期134-136,共3页
China Continuing Medical Education
